Table 2.
Trial identification | Reported name | Comparison with consensus | Percent match | SGM profile results
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
amg | D18S1179 | D21S11 | D8S1179 | FGA | TH01 | vWF | |||||
Consensus profile |
X | 16, 18 | 29 | 14 | 17, 22 | 6 | 17 | ||||
1 | 228 | ECV304 | Identical | 100 | X | 16, 18 | 29 | 14 | 17, 22 | 6 | 17 |
2 | 222 | EJ-1 (T24) | Identical | 100 | X | 16, 18 | 29 | 14 | 17, 22 | 6 | 17 |
3 | 9M | MGH-U2 | Identical | 100 | X | 16, 18 | 29 | 14 | 17, 22 | 6 | 17 |
4 | 234 | T24 | Identical | 100 | X | 16, 18 | 29 | 14 | 17, 22 | 6 | 17 |
5 | 5H | HU456 | FGA (17) loss | 100 | X | 16, 18 | 29 | 14 | 22 | 6 | 17 |
6 | 10H | HU961T | FGA (17) loss | 100 | X | 16, 18 | 29 | 14 | 22 | 6 | 17 |
7 | 18M | MGH-U2 | FGA (17) loss | 100 | X | 16, 18 | 29 | 14 | 22 | 6 | 17 |
8 | 41 | T24 | vWF (19) gain | 90 | X | 16, 18 | 29 | 14 | 17, 22 | 6 | 17, 19 |
9 | 7T | T24 | D8 (9) gain vWF (19) gain | 82 | X | 16, 18 | 29 | 9, 14 | 17, 22 | 6 | 17, 19 |
amg, amelogenin.